Hopes that phase II data could "re-ignite the investment case" for Tetralogic Pharmaceuticals Corp. flamed out and the shares (NASDAQ:TLOG) plunged 76.1 percent, or $1.29, ending at 41 cents, as the firm offered mixed results from a pair of trials.